Foralumab's multi-indication neuroinflammation bet hinges on whether na-SPMS Phase 2a and AD interim data demonstrate reproducible efficacy beyond open-label signals

Tiziana Life Sciences is a clinical-stage company developing foralumab, an intranasal therapy not yet approved, for neuroinflammatory diseases including non-active secondary progressive multiple sclerosis and Alzheimer's disease.

Foralumab, an intranasal anti-CD3 monoclonal antibody, is being developed across non-active secondary progressive MS, Alzheimer's disease, ALS, MSA, and acute spinal cord injury via a shared neuroinflammation mechanism targeting Treg induction. The thesis resolves if the INFORM-MS Phase 2a randomized controlled trial and the AD Phase 2 interim readout both show statistically meaningful efficacy signals beyond the small, uncontrolled expanded access trends. Structural risk centers on Ocrelizumab and Ofatumumab dominating progressive MS, while approved anti-amyloid antibodies Leqembi and Kisunla define the AD competitive floor that foralumab must differentiate against.